title: Clinical and prognostic factors for renal parenchymal, pelvis, and ureter cancers in SEER registries: collaborative stage data collection system, version 2.
abstract: BACKGROUND
  The American Joint Committee on Cancer's (AJCC) 7th edition cancer staging manual reflects recent changes in cancer care practices. This report assesses changes from the AJCC 6th to the AJCC 7th edition stage distributions and the quality of site-specific factors (SSFs).
  
  
  METHODS
  Incidence data for renal parenchyma and pelvis and ureter cancers from 18 Surveillance, Epidemiology, and End Results (SEER) registries were examined, including staging trends during 2004-2010, stage distribution changes between the AJCC 6th and 7th editions, and SSF completeness for cases diagnosed in 2010.
  
  
  RESULTS
  From 2004 to 2010, the percentage of stage I renal parenchyma cancers increased from 50% to 58%, whereas stage IV and unknown stage cases decreased (18% to 15%, and 10% to 6%, respectively). During this period, the percentage of stage 0a renal pelvis and ureter cancers increased from 21% to 25%, and stage IV and unknown stage tumors decreased (20% to 18%, and 7% to 5%, respectively). Stage distributions under the AJCC 6th and 7th editions were about the same. For renal parenchymal cancers, 71%-90% of cases had known values for 6 required SSFs. For renal pelvis and ureter cancers, 74% of cases were coded as known for SSF1 (WHO/ISUP grade) and 47% as known for SSF2 (depth of renal parenchymal invasion). SSF values were known for larger proportions of cases with reported resections.
  
  
  CONCLUSIONS
  Stage distributions between the AJCC 6th and 7th editions were similar. SSFs were known for more than two-thirds of cases, providing more detail in the SEER database relevant to prognosis.
authors.affiliation: National Cancer Institute, Division of Cancer Control and Population Sciences, Rockville, Maryland.
authors.forename: Sean F
authors.initials: SF
authors.lastname: Altekruse
authors.forename: Lois
authors.initials: L
authors.lastname: Dickie
authors.forename: Xiao-Cheng
authors.initials: XC
authors.lastname: Wu
authors.forename: Mei-Chin
authors.initials: MC
authors.lastname: Hsieh
authors.forename: Manxia
authors.initials: M
authors.lastname: Wu
authors.forename: Richard
authors.initials: R
authors.lastname: Lee
authors.forename: Scott
authors.initials: S
authors.lastname: Delacroix
mesh_terms: D002292:Carcinoma, Renal Cell / Q000473:pathology*; D002295:Carcinoma, Transitional Cell / Q000473:pathology*; D015331:Cohort Studies; D006801:Humans; D007680:Kidney Neoplasms / Q000473:pathology*; D007682:Kidney Pelvis; D008198:Lymph Nodes / Q000473:pathology*; D060787:Neoplasm Grading; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging / Q000639:trends; D011379:Prognosis; D012042:Registries; D012082:Renal Veins; D012189:Retrospective Studies; D018426:SEER Program; D014516:Ureteral Neoplasms / Q000473:pathology*
keywords: AJCC collaborative stage; cancer; kidney; renal pelvis; site-specific factors